Skip to main content
. 2020 Apr 24;11:505. doi: 10.3389/fphar.2020.00505

Figure 6.

Figure 6

Relationship between metabolic type and drug concentration. homEM, homozygous extensive metabolizer; hetEM, heterozygous extensive metabolizer; PM, poor metabolizer. The total Cmin of VRC in day 4 and day 10 in homEM [(day 4, n = 26, 712.7 ± 446.9 ng/ml), (day 10, n = 13, 641.2 ± 532.0 ng/ml)]was significantly lower than PM [(day 4, n = 11,1356.0 ± 519.6 ng/ml, p = 0.025), (day 10, n = 8, 1567.4 ± 523.0 ng/ml, p = 0.011), shown in (A)]. The unbound Cmin of VRC in day 4 in PM [n = 6, 874.6 ± 304.6 ng/ml] was significantly higher than that in homEM [n = 6, 350.8 ± 152.5 ng/ml, p < 0.01] and hetEM [n = 6, 548.9 ± 144.0, p=0.019], shown in (B). The unbound Cmin of VRC in day 10 (shown in B) in homEM [n = 7, 215.2 ± 132.6 ng/ml] was significantly lower than that in hetEM [n = 6, 562.3 ± 147.7 ng/ml, p < 0.01] and PM [n = 6, 957.6 ± 502.8 ng/ml, p < 0.01]. There was no similar relationship between metabolic type and Cmax (C, D).